House bill in the works to deter brand product switches should specify what behavior would be unacceptable, legal experts testify at congressional hearing.
As Rep. Jan Schakowsky, D-Ill, plans to introduce a bill targeted at brand manufacturer product hopping, legal experts offered advice on how to assure it is not too broad or vague as to interfere with normal business practices.
Schakowsky announced that she was working on the legislation at a 19 September hearing of the House Energy and Commerce Subcommittee on Consumer Protection and Commerce. The hearing, entitled "Profits...
Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.
The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
